Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Different levels of lack of improvement at 4 weeks of escitalopram treatment as predictors of poor 8-week outcome in MDD.

Gilaberte I, Romera I, Perez-Sola V, Menchon JM, Schacht A.

J Affect Disord. 2013 Apr 25;146(3):433-7. doi: 10.1016/j.jad.2012.07.035. Epub 2012 Aug 23.

PMID:
22921481
2.

Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.

Henkel V, Seemüller F, Obermeier M, Adli M, Bauer M, Mundt C, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Mayr A, Möller HJ, Riedel M.

J Affect Disord. 2009 Jun;115(3):439-49. doi: 10.1016/j.jad.2008.10.011. Epub 2008 Nov 22.

PMID:
19027961
3.

Early symptom change prediction of remission in depression treatment.

Katz MM, Meyers AL, Prakash A, Gaynor PJ, Houston JP.

Psychopharmacol Bull. 2009;42(1):94-107.

PMID:
19204654
4.

Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.

Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM.

Curr Med Res Opin. 2007 Jun;23(6):1303-18. Epub 2007 Apr 27.

PMID:
17559729
5.
6.

[Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].

Azorin JM, Llorca PM, Despiegel N, Verpillat P.

Encephale. 2004 Mar-Apr;30(2):158-66. French.

PMID:
15107719
7.

Rapid improvement of depression and quality of life with escitalopram treatment in outpatients with breast cancer: a 12-week, open-label prospective trial.

Park HY, Lee BJ, Kim JH, Bae JN, Hahm BJ.

Prog Neuropsychopharmacol Biol Psychiatry. 2012 Mar 30;36(2):318-23. doi: 10.1016/j.pnpbp.2011.11.010. Epub 2011 Nov 28.

PMID:
22142651
8.

Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.

Nierenberg AA, Greist JH, Mallinckrodt CH, Prakash A, Sambunaris A, Tollefson GD, Wohlreich MM.

Curr Med Res Opin. 2007 Feb;23(2):401-16.

PMID:
17288694
9.

Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD).

Wade AG, Schlaepfer TE, Andersen HF, Kilts CD.

J Psychiatr Res. 2009 Feb;43(5):568-75. doi: 10.1016/j.jpsychires.2008.09.008. Epub 2008 Oct 26.

PMID:
18954875
10.

Baseline severity of depression predicts antidepressant drug response relative to escitalopram.

Kilts CD, Wade AG, Andersen HF, Schlaepfer TE.

Expert Opin Pharmacother. 2009 Apr;10(6):927-36. doi: 10.1517/14656560902849258 .

PMID:
19317630
11.

[Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].

Favré P.

Encephale. 2012 Feb;38(1):86-96. doi: 10.1016/j.encep.2011.11.003. Epub 2011 Dec 10. Review. French.

PMID:
22381728
12.

Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder.

Lepola U, Wade A, Andersen HF.

Int Clin Psychopharmacol. 2004 May;19(3):149-55. Erratum in: Int Clin Psychopharmacol. 2004 Jul;19(4):255.

PMID:
15107657
13.

Early vs. conventional switching of antidepressants in patients with MDD and moderate to severe pain: a double-blind randomized study.

Romera I, Pérez V, Menchón JM, Schacht A, Papen R, Neuhauser D, Abbar M, Picard H, Gilaberte I.

J Affect Disord. 2012 Dec 20;143(1-3):47-55. doi: 10.1016/j.jad.2012.05.024. Epub 2012 Aug 1.

PMID:
22858211
14.
16.

Early improvement and serum concentrations of citalopram to predict antidepressant drug response of patients with major depression.

Ostad Haji E, Tadic A, Wagner S, Dragivevic A, Müller MJ, Boland K, Rao ML, Fric M, Laux G, Hiemke C.

Pharmacopsychiatry. 2013 Nov;46(7):261-6. doi: 10.1055/s-0033-1354370. Epub 2013 Sep 24.

PMID:
24065567
17.

Escitalopram in the treatment of major depressive disorder: a meta-analysis.

Kennedy SH, Andersen HF, Thase ME.

Curr Med Res Opin. 2009 Jan;25(1):161-75. doi: 10.1185/03007990802622726 .

PMID:
19210149
18.

Quantitative electroencephalogram biomarkers for predicting likelihood and speed of achieving sustained remission in major depression: a report from the biomarkers for rapid identification of treatment effectiveness in major depression (BRITE-MD) trial.

Cook IA, Hunter AM, Gilmer WS, Iosifescu DV, Zisook S, Burgoyne KS, Howland RH, Trivedi MH, Jain R, Greenwald S, Leuchter AF.

J Clin Psychiatry. 2013 Jan;74(1):51-6. doi: 10.4088/JCP.10m06813.

PMID:
23419226
19.

Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.

Lam RW, Lönn SL, Despiégel N.

Int Clin Psychopharmacol. 2010 Jul;25(4):199-203. doi: 10.1097/YIC.0b013e32833948d8.

PMID:
20357664
20.

Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder.

Leuchter AF, Cook IA, Gilmer WS, Marangell LB, Burgoyne KS, Howland RH, Trivedi MH, Zisook S, Jain R, Fava M, Iosifescu D, Greenwald S.

Psychiatry Res. 2009 Sep 30;169(2):132-8. doi: 10.1016/j.psychres.2009.04.004. Epub 2009 Aug 26.

PMID:
19709754

Supplemental Content

Support Center